Dr. Robert Holloway’s manuscript titled, “Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination With Carboplatin Versus Gemcitabine/Carboplatin for the Treatment of Platinum Sensitive Recurrent Ovarian Cancer: A Systematic Review,” has been accepted for publication by The Oncologist- The official journal of the Society for Translational Oncology. This manuscript was reviewed by Section Editors at The Oncologist and other external experts in the field.
Congratulations to Dr. Holloway for the scientific advancement that this manuscript represents.
Tuesday, October 25, 2011
